GPR55 and atherosclerosis: Studies using the GPR55 antagonist CID16020046 and agonists (AM251 and Abn-CBD) in ApoE-/- mice models of atherosclerosis revealed that GPR55 modulation affects neutrophil function depending on atherogenic progression and diet.